Novavax, Inc. Reports Fourth-Quarter And Year-End 2013 Financial Results And Initiation Of Phase 1/2 Clinical Trial Of Its H7N9 Avian Influenza VLP Vaccine Candidate With Matrix-M™

GAITHERSBURG, Md., March 10, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today reported its financial results for the fourth quarter and year ended December 31, 2013 and announced the initiation of a Phase 1/2 clinical trial of its H7N9 avian influenza VLP vaccine candidate with its proprietary Matrix-M adjuvant. The trial is enrolling 610 healthy subjects to evaluate the safety and immunogenicity of this vaccine and adjuvant.

Help employers find you! Check out all the jobs and post your resume.